nyselly
ValueWalk
Supply shortages have complicated the pharmaceutical industry.Eli Lilly & Co are making the right pivots.New partnerships aimed at new products show great promise.The dividend is healthy, and long-term growth looks good.5 stocks we like better than Eli Lilly andHeading into the week before Christmas, the United States Food and Drug Administration flagged Eli Lilly & Co. (NYSE:LLY) for a shortage of their new diabetes drug, Mounjaro. They are also having supply issues with their previous diabetes medicine, Trulicity, which is the pharmaceutical company’s best-selling drug of all time. Q3 2022 h...
ValueWalk
CNBC transcript: Eli Lilly And Co (NYSE:LLY) Chairman & CEO David Ricks speaks with Meg Tirrell live during CNBC’s Healthy Returns Summit today Q1 2021 hedge fund letters, conferences and more WHEN: Today, Tuesday, May 11 WHERE: CNBC’s “Healthy Returns Summit: New Era of Innovation” CNBC's Interview With Eli Lilly CEO David RicksTYLER MATHISEN: More than six million Americans have Alzheimer's disease, and that number predicted to escalate more than double by 2015, yet the FDA has not approved a new drug to treat the disease since 2003. Our next guest is hoping to change that. David Ricks is th...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら